Cargando…

Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study

BACKGROUND: This retrospective, multicenter study evaluated the effect of pemafibrate treatment on liver function and fibrosis by liver function tests (LFTs) and various fibrotic biomarkers including FibroScan in non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia. METHODS: A total o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morishita, Asahiro, Oura, Kyoko, Takuma, Kei, Nakahara, Mai, Tadokoro, Tomoko, Fujita, Koji, Tani, Joji, Shi, Tingting, Himoto, Takashi, Tatsuta, Miwa, Moriya, Akio, Senoo, Tomonori, Tsutsui, Akemi, Nagano, Takuya, Takaguchi, Koichi, Ono, Masafumi, Masaki, Tsutomu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224826/ https://www.ncbi.nlm.nih.gov/pubmed/36583842 http://dx.doi.org/10.1007/s12072-022-10453-1

Ejemplares similares

Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study
por: Tani, Joji, et al.
Publicado: (2021)

Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy
por: Oura, Kyoko, et al.
Publicado: (2023)

Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study
por: Tani, Joji, et al.
Publicado: (2020)

Albumin–bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C
por: Fujita, Koji, et al.
Publicado: (2019)

Nutritional Support for Alcoholic Liver Disease
por: Tadokoro, Tomoko, et al.
Publicado: (2023)

Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease
por: Manabe, Takushi, et al.
Publicado: (2023)

Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study
por: Morishita, Asahiro, et al.
Publicado: (2021)

Galectin-9 ameliorates fulminant liver injury
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells
por: Nakahara, Mai, et al.
Publicado: (2022)

Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
por: Ikeda, Suguru, et al.
Publicado: (2021)

Albumin–Bilirubin Score Differentiates Liver Fibrosis Stage and Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Virus Infection: A Retrospective Cohort Study
por: Fujita, Koji, et al.
Publicado: (2019)

Cisplatin in Liver Cancer Therapy
por: Hamaya, Sae, et al.
Publicado: (2023)

Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA
por: Tadokoro, Tomoko, et al.
Publicado: (2021)

Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines
por: Takuma, Kei, et al.
Publicado: (2022)

Peg-IFNα-2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up
por: Tadokoro, Tomoko, et al.
Publicado: (2021)

Clinical efficacy of free androgen index, a surrogate hallmark of circulating free testosterone level, in male patients with HCV-related chronic liver disease
por: Himoto, Takashi, et al.
Publicado: (2018)

Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis
por: Shi, Tingting, et al.
Publicado: (2020)

MicroRNAs and Nonalcoholic Steatohepatitis: A Review
por: Morishita, Asahiro, et al.
Publicado: (2023)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
por: Sugimoto, Ryosuke, et al.
Publicado: (2023)

Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature
por: Oura, Kyoko, et al.
Publicado: (2021)

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Albumin platelet product as a novel score for liver fibrosis stage and prognosis
por: Fujita, Koji, et al.
Publicado: (2021)

Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease
por: Shinozaki, Satoshi, et al.
Publicado: (2020)

Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy
por: Minamikawa, Takeo, et al.
Publicado: (2022)

Galectin-9 suppresses the tumor growth of colon cancer in vitro and in vivo
por: Morishita, Asahiro, et al.
Publicado: (2021)

Verification of B-lymphocyte activating factor’s involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease
por: Himoto, Takashi, et al.
Publicado: (2017)

Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis
por: Fujita, Koji, et al.
Publicado: (2019)

MicroRNA Interference in Hepatic Host-Pathogen Interactions
por: Morishita, Asahiro, et al.
Publicado: (2021)

MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review
por: Morishita, Asahiro, et al.
Publicado: (2021)

Giant cutaneous metastasis from hepatocellular carcinoma
por: Morishita, Asahiro, et al.
Publicado: (2022)

Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma
por: Kohno, Tomoki, et al.
Publicado: (2020)

Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease
por: Ishikawa, Toru, et al.
Publicado: (2023)

Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice
por: Iitake, Chie, et al.
Publicado: (2019)

A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy
por: Oura, Kyoko, et al.
Publicado: (2023)

Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
por: Meroni, Marica, et al.
Publicado: (2022)

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients
por: Fujita, Koji, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nlqmfr5jvgp0e6aopnj7elsl36